BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
Get Our Industry eNewsletter FREE email:    
   

ABT Molecular Imaging Announces $9 Million Financing


10/6/2009 8:47:58 AM

Bookmark and Share

KNOXVILLE, TN – October 6, 2009 – ABT Molecular Imaging, a medical imaging company developing a production platform to generate unit doses of molecular imaging drugs, announced today it has secured a $9 million round of financing.

Venture capital firm Intersouth Partners led the $9 million Series A financing, with company founders participating. The round, which will be used to complete product development and execute an initial sales strategy, is the company’s first outside financing.

ABT’s technology proposes to make doses of molecular imaging drugs for positron emission tomography (PET scanning) at the point of use. PET scanners map the body by means of injectable radioactive drugs that allow PET machines to highlight areas of abnormal metabolic function indicative of disease. This imaging drug production currently requires massive and expensive machinery, generally limiting its use to large academic medical centers and large pharmaceutical manufacturers in certain geographies.

ABT’s Biomarker Generator will enable rapid, safe and local production of PET imaging agents in a way that is more convenient, versatile and significantly less expensive than current methods available. The company was founded by industry veteran Ronald Nutt, Ph.D., a leader in the molecular imaging industry.

“We’re excited about working with ABT,” said Dennis Dougherty of Intersouth Partners. “Dr. Nutt’s expertise in this industry, coupled with the company’s innovative technology and ability to make a real impact in the delivery of diagnostic services make this a very interesting opportunity.”

“This investment in ABT is a tremendous endorsement of the market opportunity our technology provides,” said Ronald Nutt, Ph.D., Founder and Chairman of ABT Molecular Imaging. “Having grown the company over the last three years, this infusion of capital will allow us to accelerate that growth, enabling our ability to bring this innovative technology to market.”

About ABT Molecular Imaging ABT Molecular Imaging is a medical imaging company developing a production platform to generate unit doses of molecular imaging drugs for positron emission tomography at the point of use. The company was founded in 2006 by industry experts in the molecular imaging industry.

Contacts Lynda Nutt ABT Molecular Imaging 865.982.0098 lnutt@biomarker-technologies.com


Read at BioSpace.com


   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES
 

//-->